Latest Period
Q1 2026
Security Snapshot
Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) Institutional Ownership
CUSIP: 890260839
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
81
Shares (Excl. Options)
4,869,103
Price
$13.75
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TNXP on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 4,869,103
- Total 13F value
- $66,966,212
- Portfolio coverage rank
- 0%
- Share change
- +661,178
- Value change
- +$8,767,315
- Number of holders
- 81
- Shares outstanding
- 13,418,426
- SEC-reported price per share
- $13.84
- Insider filing price
- $13.84
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TNXP - Tonix Pharmaceuticals Holding Corp. - Common Stock is tracked under CUSIP 890260839.
- 81 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 70 to 81 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $58,486,083 to $66,966,212.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 81 institutions filings for Q1 2026.
Security key
890260839
Latest holder period
Q1 2026
13F holders
81
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
TNXP full holder history
Tonix Pharmaceuticals Holding Corp. SEC filings
Tonix Pharmaceuticals Holding Corp. company facts
Tonix Pharmaceuticals Holding Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 890260839:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TNXP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9.2% | $19,884,434 | 1,235,058 | Point72 Asset Management, L.P. | 29 Dec 2025 | |||
| BlackRock, Inc. | 6.7% | -14% | $13,348,524 | +$2,726,362 | 854,579 | +26% | BlackRock, Inc. | 31 Dec 2025 |
| VANGUARD GROUP INC | 5% | -22% | $10,521,710 | +$1,822,042 | 673,605 | +21% | The Vanguard Group | 31 Dec 2025 |
As of 31 Mar 2026, 81 institutional investors reported holding 4,869,103 shares of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP). This represents 36% of the company’s total 13,418,426 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | 968,177 | +9.4% | 0% | $13,312,434 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 518,650 | 0% | 0% | $7,131,438 |
| CITADEL ADVISORS LLC | 3.5% | 468,712 | 0% | $6,444,790 | |
| Jones Hill Capital LP | 3.4% | 452,116 | 0% | 1.3% | $6,216,595 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 313,291 | +15% | 0% | $4,308,912 |
| Balyasny Asset Management L.P. | 2.3% | 313,082 | +69% | 0.01% | $4,304,878 |
| UBS Group AG | 1.7% | 231,678 | +153% | 0% | $3,185,573 |
| STATE STREET CORP | 1.7% | 230,607 | +20% | 0% | $3,170,846 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 219,673 | +857% | 0% | $3,020,504 |
| AQR CAPITAL MANAGEMENT LLC | 1.2% | 161,208 | +705% | 0% | $2,216,611 |
| Point72 Asset Management, L.P. | 0.93% | 125,414 | -80% | 0% | $1,724,443 |
| NORTHERN TRUST CORP | 0.75% | 100,134 | -43% | 0% | $1,376,844 |
| Nuveen, LLC | 0.7% | 94,561 | +1.2% | 0% | $1,300,214 |
| VANGUARD FIDUCIARY TRUST CO | 0.63% | 84,270 | 0% | 0% | $1,158,713 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.59% | 78,627 | 0% | 0% | $1,081,121 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.47% | 63,540 | 0.62% | $873,675 | |
| BANK OF AMERICA CORP /DE/ | 0.45% | 60,958 | +101% | 0% | $838,173 |
| GOLDMAN SACHS GROUP INC | 0.4% | 53,055 | +98% | 0% | $729,506 |
| Bank of New York Mellon Corp | 0.23% | 30,426 | +26% | 0% | $418,352 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.22% | 29,790 | -11% | 0% | $409,613 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.22% | 29,579 | -0.28% | 0% | $406,711 |
| Quadrature Capital Ltd | 0.13% | 17,410 | 0% | $239,388 | |
| MORGAN STANLEY | 0.13% | 17,270 | -59% | 0% | $237,462 |
| Invesco Ltd. | 0.11% | 15,265 | 0% | $209,895 | |
| IEQ CAPITAL, LLC | 0.11% | 14,358 | 0% | $197,423 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,869,103 | $66,966,212 | +$8,767,315 | $13.75 | 81 |
| 2025 Q4 | 3,742,749 | $58,486,083 | +$19,805,765 | $15.62 | 70 |
| 2025 Q3 | 2,357,754 | $56,965,413 | +$23,004,291 | $24.16 | 60 |
| 2025 Q2 | 1,387,298 | $49,914,163 | +$34,081,287 | $35.98 | 46 |
| 2025 Q1 | 473,835 | $8,469,550 | +$8,375,403 | $17.88 | 24 |
| 2024 Q4 | 5,377 | $1,773 | +$1,773 | $0.33 | 2 |